These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31654627)

  • 21. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
    Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.
    Hwang J; Song I; Lee K; Kim HR; Hong EH; Hwang JS; Ahn SH; Lee J
    Invest New Drugs; 2020 Oct; 38(5):1282-1291. PubMed ID: 31956933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
    Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
    Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
    Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
    Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis.
    McDonnell SR; Hwang SR; Basrur V; Conlon KP; Fermin D; Wey E; Murga-Zamalloa C; Zeng Z; Zu Y; Elenitoba-Johnson KS; Lim MS
    Oncogene; 2012 Aug; 31(32):3733-40. PubMed ID: 22179823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
    Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
    Oncogene; 2003 Aug; 22(35):5399-407. PubMed ID: 12934099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
    Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
    Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
    Garces de Los Fayos Alonso I; Zujo L; Wiest I; Kodajova P; Timelthaler G; Edtmayer S; Zrimšek M; Kollmann S; Giordano C; Kothmayer M; Neubauer HA; Dey S; Schlederer M; Schmalzbauer BS; Limberger T; Probst C; Pusch O; Högler S; Tangermann S; Merkel O; Schiefer AI; Kornauth C; Prutsch N; Zimmerman M; Abraham B; Anagnostopoulos J; Quintanilla-Martinez L; Mathas S; Wolf P; Stoiber D; Staber PB; Egger G; Klapper W; Woessmann W; Look TA; Gunning P; Turner SD; Moriggl R; Lagger S; Kenner L
    Mol Cancer; 2022 Aug; 21(1):172. PubMed ID: 36045346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
    Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
    Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
    Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
    Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.
    Ambrogio C; Martinengo C; Voena C; Tondat F; Riera L; di Celle PF; Inghirami G; Chiarle R
    Cancer Res; 2009 Nov; 69(22):8611-9. PubMed ID: 19887607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
    Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
    Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
    Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
    Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
    Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
    Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.